weekly biotechnology news wrap up

March 3, 2017

March 3, 2017

This week’s headlines include: Kite Pharma shares soar after cancer therapy study shows good results, Deadly, Drug-Resistant ‘Superbugs’ Pose Huge Threat, W.H.O. Says, Activating a cell-protecting protein could ward off Alzheimer’s symptoms, China’s Bird Flu Surge Is a Low Epidemic Threat, W.H.O. Says, Advaxis Inks Deal with Sellas to Develop New Cancer Immunotherapy, Cypralis Wins ADDF Funding to Support Cyclophilin D Inhibitor Program, and ILS Automation launches micro-pumps to provide precise control at low flow.


“Kite Pharma shares soar after cancer therapy study shows good results,” The Los Angeles Times

“An experimental gene therapy that turns a patient’s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, Kite Pharma Inc. said Tuesday…”

“Deadly, Drug-Resistant ‘Superbugs’ Pose Huge Threat, W.H.O. Says,” The New York Times

“The World Health Organization warned on Monday that a dozen antibiotic-resistant “superbugs” pose an enormous threat to human health, and urged hospital infection-control experts and pharmaceutical researchers to focus on fighting the most dangerous pathogens first…”

“Activating a cell-protecting protein could ward off Alzheimer’s symptoms,” Fierce Biotech

“University College London scientists have identified the inhibitor of a cell-protecting protein as a promising new target in treating Alzheimer’s disease. They tested the approach in fruit fly and mouse models and hope to translate their work to human nerve cells…”

“China’s Bird Flu Surge Is a Low Epidemic Threat, W.H.O. Says,” The New York Times

“Although there has been a surge in human infections with H7N9 avian flu in China this winter, the risk of an epidemic remains low, a World Health Organization official said on Wednesday…”

“Advaxis Inks Deal with Sellas to Develop New Cancer Immunotherapy,” Xconomy

“Advaxis and Sellas Life Sciences Group, two companies that have pursued different ways of prompting the body’s immune system to fight cancer, are now hoping that combining their efforts will lead to a more precise treatment…”

“Cypralis Wins ADDF Funding to Support Cyclophilin D Inhibitor Program,” Genetic Engineering News

“U.K.-based Cypralis has been awarded $524,000 by the Alzheimer’s Drug Discovery Foundation (ADDF). The firm said the award will support its existing neurodegenerative disease therapeutics partnership with Janssen Pharmaceuticals…”

“ILS Automation launches micro-pumps to provide precise control at low flow,” Filtration and Separation

“Designed for cell-culture and fermentation applications in bench-to-pilot scale reactors, the AFC 928 offers precise control over very low flow applications down to 0.05 ml/hr, allowing labs to replace their external syringe pumps with fully integrated peristaltic pumps…”

Recent Articles on Cell Culture Dish & Downstream Column:

Cell Culture Dish

Downstream Column logo tall

Cool Tool – New KANEKA KanCapA™ 3G for Improved Binding and Milder Elution of Therapeutic Antibodies

Continuous Processing Optimization with Smarter Tools

Increasing Downstream Bioprocess Efficiency and Overcoming Bottlenecks

Lowering MAb Clinical Trial Material Manufacturing Costs with Purpose-designed Protein A Chromatography Resins – A Case Study

Cell Culture Events:

World Vaccine Congress – April 10-12, 2017, Washington D.C.

The 17th Annual World Vaccine Congress is the place where the global vaccine industry meets to discuss commercial and scientific issues around regulation, strategy, manufacturing, trials, partnering, influenza, cancer, emerging diseases and veterinary vaccines.

Across 150 sessions, you will learn from leading experts across the issues most impacting on the wider vaccine sector, as well as delve into your specialist area of research and job focus in co-located conferences.

Meet over 700 of your peers in one room and take advantage of the multiple extended networking breaks, co-located World Vaccine Congress (including 7 streams on Immune Profiling, Cancer & Immunotherapy, Influenza & Respiratory, Clinical Trials, Emerging Diseases, Partnerships, Veterinary Vaccines and Bioprocessing & Manufacturing) as well as the evening drinks reception.

For more information, please visit the website https://goo.gl/nJ2bZ1

Cell Culture World Congress USA 2017 – May 24, 2017, Hilton San Diego Resort and Spa, San Diego, CA

The vision of Cell Culture World USA is to provide new, relevant content on process development for cell culture specific scientists working in bio manufacturing companies developing antibodies and immunotherapies. Over 4 years, the Congress has become a technical and networking forum for bioprocessing professionals to provide cutting-edge commentary, present novel and never-before-seen case studies, and highlight technological advancements to the industry.

Our 2017 event will feature a more focused structure, zeroing in on the topics that interest cell-culture specific scientists the most. Immunotherapies are the talk of the industry, and they’ll be a huge topic for this year’s event as well.

Download Brochure: https://goo.gl/t5ZRvx

Register now: https://goo.gl/KTOdxq


Continuous Bioprocessing Solutions: An Update on Significant Enabling Technology Advances – March 7, 2017

While continuous processing has been applied for several decades, the highly regulated biopharm industry has just started to embrace this approach. The team at Pall Life Sciences has leveraged an industry-leading single-use portfolio to deliver innovative continuous bioprocessing solutions to the market. Join our team as they detail the development journey, and highlight critical advances to date.